Merck KGaA
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.6M
Doctors Paid
135
Transactions
551
2024 Total
$135,164
Payment Breakdown by Category
Research$2.3M (64.4%)
Consulting$730,219 (20.5%)
Travel$106,706 (3.0%)
Royalty/License$18,000 (0.5%)
Food & Beverage$2,468 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 141 | 64.4% |
| Consulting Fee | $730,219 | 200 | 20.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $409,305 | 117 | 11.5% |
| Travel and Lodging | $106,706 | 67 | 3.0% |
| Royalty or License | $18,000 | 2 | 0.5% |
| Food and Beverage | $2,468 | 24 | 0.1% |
Payments by Type
Research
$2.3M
141 transactions
General
$1.3M
410 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors | $520,736 | 0 | 29 |
| A Phase I Open Label First in Human Dose Escalation and Expansion Study of the Bispecific Anti-Mucin 1 - Epidermal Growth Factor Receptor Antibody Drug Conjugate M1231 as a Single Agent in Participants with Advanced Solid Tumors | $58,888 | 0 | 14 |
| A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | $17,550 | 0 | 7 |
| A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX) | $15,175 | 0 | 22 |
| MS 700568-0002 | $8,010 | 2 | 5 |
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | $3,315 | 0 | 6 |
| A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study). | $1,905 | 0 | 3 |
| A Phase I, Two-Part, Multicenter, Open-Label First in Human Study of anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants with Advanced Solid Tumors | $1,627 | 0 | 22 |
| A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of anti-GD2 Antibody Drug Conjugate M3554 in Participants with Advanced Solid Tumors | $1,223 | 0 | 14 |
| A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin | $1,184 | 0 | 4 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Neurology | $531,998 | 46 | $11,565 |
| Internal Medicine | $188,618 | 16 | $11,789 |
| Medical Oncology | $167,958 | 14 | $11,997 |
| Hematology & Oncology | $85,588 | 13 | $6,584 |
| Specialist | $51,903 | 4 | $12,976 |
| Radiation Oncology | $39,362 | 4 | $9,841 |
| Obstetrics & Gynecology | $34,688 | 5 | $6,938 |
| Endocrinology, Diabetes & Metabolism | $25,388 | 3 | $8,463 |
| Allergy & Immunology | $13,849 | 1 | $13,849 |
| Otolaryngology | $13,755 | 1 | $13,755 |
| Cardiovascular Disease | $11,138 | 1 | $11,138 |
| Pediatric Infectious Diseases | $11,022 | 1 | $11,022 |
| Ophthalmology | $10,980 | 2 | $5,490 |
| Reproductive Endocrinology | $10,019 | 2 | $5,010 |
| Interventional Cardiology | $8,288 | 1 | $8,288 |
| Physical Medicine & Rehabilitation | $7,014 | 1 | $7,014 |
| Gynecologic Oncology | $5,800 | 4 | $1,450 |
| Psychiatry | $5,750 | 1 | $5,750 |
| Trauma Surgery | $5,746 | 1 | $5,746 |
| Anatomic Pathology & Clinical Pathology | $4,935 | 2 | $2,468 |
| Adult Health | $3,290 | 1 | $3,290 |
| Neuromuscular Medicine | $2,760 | 2 | $1,380 |
| Infectious Disease | $2,720 | 1 | $2,720 |
| Rheumatology | $2,528 | 1 | $2,528 |
| Pediatrics | $2,220 | 1 | $2,220 |
| Gastroenterology | $2,190 | 1 | $2,190 |
| Pediatric Hematology-Oncology | $2,070 | 1 | $2,070 |
| Hematology | $1,725 | 1 | $1,725 |
| Diagnostic Radiology | $1,425 | 1 | $1,425 |
| Urology | $1,035 | 1 | $1,035 |
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Robert Ferris, Md, MD | Otolaryngology | Raleigh, NC | $13,755 | $0 |
| Gerard Letterie, Do, DO | Obstetrics & Gynecology | Kirkland, WA | $13,708 | $0 |
| Dr. Christian Rolfo, Md, MD | Medical Oncology | Columbus, OH | $12,750 | $0 |
| Timothy Yap, Md, MD | Medical Oncology | Houston, TX | $12,486 | $0 |
| Ari Rosenberg, Md, MD | Hematology & Oncology | Chicago, IL | $12,392 | $0 |
| Dr. Stephen Krieger, Md, MD | Neurology | New York, NY | $12,292 | $0 |
| Edmund Kopetz, M.d, M.D | Medical Oncology | Houston, TX | $12,270 | $0 |
| Dr. Mitchell Rosen, M.d, M.D | Obstetrics & Gynecology | San Francisco, CA | $12,040 | $0 |
| Dr. Kamal Henderson, Md, MD | Cardiovascular Disease | Winston Salem, NC | $11,138 | $0 |
| Jeanny Aragon-Ching, M.d, M.D | Internal Medicine | Falls Church, VA | $11,040 | $0 |
| James Crowe, Md, MD | Pediatric Infectious Diseases | Nashville, TN | $11,022 | $0 |
| Brent Egan, Md, MD | Internal Medicine | Greenville, SC | $10,649 | $0 |
| Le Hua, M.d, M.D | Neurology | Las Vegas, NV | $9,855 | $0 |
| Antonio Bianco, M.d, M.D | Internal Medicine | Chicago, IL | $9,739 | $0 |
| Dr. Fred Lublin, M.d, M.D | Neurology | New York, NY | $9,540 | $0 |
| Dr. Anne Cross, Md, MD | Neurology | Saint Louis, MO | $9,175 | $0 |
| Nabil Saba, M.d, M.D | Medical Oncology | Atlanta, GA | $9,063 | $0 |
| Barry Singer | Neurology | Saint Louis, MO | $8,770 | $0 |
| Nancy Lee, Md, MD | Radiation Oncology | New York, NY | $8,625 | $0 |
| Dr. Ricardo Azziz, Md, MD | Reproductive Endocrinology | Augusta, GA | $8,519 | $0 |
| Barbara Burtness, M.d, M.D | Interventional Cardiology | New Haven, CT | $8,288 | $0 |
| Ami Bhatt, Md, MD | Hematology & Oncology | Stanford, CA | $7,971 | $0 |
| David Camidge, Md, MD | Medical Oncology | Aurora, CO | $7,760 | $0 |
| Gabriel Pardo, M.d, M.D | Neurology | Oklahoma City, OK | $7,560 | $0 |
| Dr. David Cooper, M.d, M.D | Internal Medicine | Baltimore, MD | $7,532 | $0 |
Ad
Top Products
- M6223 and Bintrafusp alfa $518,210
- MSC2571458 $280,800
Associated Products (4)
- M6223 and Bintrafusp alfa $518,210
- MSC2571458 $280,800
- immunoproteasome inhibitors $206,489
- Erbitux $24,709
Payment Categories
- Food & Beverage $2,468
- Consulting $730,219
- Travel & Lodging $106,706
- Research $2.3M
- Royalties $18,000
About Merck KGaA
Merck KGaA has made $3.6M in payments to 135 healthcare providers, recorded across 551 transactions in the CMS Open Payments database. In 2024, the company paid $135,164. The top product by payment volume is M6223 and Bintrafusp alfa ($518,210).
Payments were distributed across 30 medical specialties. The top specialty by payment amount is Neurology ($531,998 to 46 doctors).
Payment categories include: Food & Beverage ($2,468), Consulting ($730,219), Research ($2.3M), Travel & Lodging ($106,706), Royalties ($18,000).
Merck KGaA is associated with 4 products in the CMS Open Payments database, including M6223 and Bintrafusp alfa, MSC2571458, and immunoproteasome inhibitors.